Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

Ratios

vs
industry
vs
history
P/E(ttm) 21.80
XTL's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XTL: 21.80 )
Ranked among companies with meaningful P/E(ttm) only.
XTL' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 23.39
Current: 21.8
0
23.39
PE(NRI) 21.80
XTL's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XTL: 21.80 )
Ranked among companies with meaningful PE(NRI) only.
XTL' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 23.39
Current: 21.8
0
23.39
P/B 2.18
XTL's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XTL: 2.18 )
Ranked among companies with meaningful P/B only.
XTL' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.23
Current: 2.18
0
2.23

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.14
XTL's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XTL: 1.14 )
Ranked among companies with meaningful Dividend Yield only.
XTL' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.25
Current: 1.14
0
1.25
Yield on cost (5-Year) 1.13
XTL's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. XTL: 1.13 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
XTL' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 1.25
Current: 1.13
0
1.25

More Statistics

Short Percentage of Float0.00%
52-Week Range $47.16 - 69.51
Shares Outstanding (Mil)600,000.00
» More Articles for XTL

Headlines

Articles On GuruFocus.com
Bill Ackman Comments on Herbalife Dec 09 2016 
Bill Ackman Comments on Nomad Dec 09 2016 
Bill Ackman Comments on Platform Specialty Products Corp Dec 09 2016 
Bill Ackman Comments on Valeant Pharmaceuticals International Dec 09 2016 
Bill Ackman Comments on Fannie Mae and Freddie Mac Dec 09 2016 
Bill Ackman Comments on The Howard Hughes Corp Dec 09 2016 
Bill Ackman Comments on Restaurant Brands International Dec 09 2016 
Bill Ackman Comments on Air Products Dec 09 2016 
Bill Ackman Comments on Mondelez Dec 09 2016 
Bill Ackman Comments on Chipotle Mexican Grill Dec 09 2016 

More From Other Websites
XTL Biopharmaceuticals Receives NASDAQ Notification Regarding Minimum Bid Requirements Nov 09 2016
Fed Holds Off Rate Hike for Now: Top 5 Gainers Sep 22 2016
After Friday's Swoon, Should You Run for the Exits? Sep 11 2016
XTL Biopharmaceuticals Announces the European Patent Office has Issued a Patent for its Lupus Drug... Sep 07 2016
XTL Biopharmaceuticals to Present at Rodman & Renshaw Conference on September 12, 2016 Sep 06 2016
Top ETFs In Neglected Telecom Sector Sep 01 2016
XTL Biopharmaceuticals Announces New Patent Filing in U.S. for Lupus Drug hCDR1 Aug 11 2016
Dow ETF Treads Water As Key Blue Chips Post Results That Lack Salt Jul 26 2016
Thursday links: a tightrope walk May 26 2016
XTL Biopharmaceuticals to Present at ChinaBio Partnering Forum 2016 in Suzhou, China on May 19, 2016 May 16 2016
New highs for the market? May 09 2016
Where to Invest if the Fed Stays Dovish (XLU,XTL) Apr 14 2016
Triple digit gains in Dow Apr 12 2016
XTL Biopharmaceuticals Completes Phase 2 Trial Design for Lead Compound hCDR1 in the Treatment of... Mar 21 2016
Lupus Thought Leader Daphna Paran, MD, Named Medical Director of XTL Biopharmaceuticals Mar 09 2016
XTL Biopharmaceuticals Expands Global IP Portfolio With Issued Patent in Hungary for Lupus Drug... Mar 02 2016
XTL Biopharmaceuticals Receives European Medicines Agency's SME Status Feb 22 2016
XTL Biopharmaceuticals' Lupus Drug hCDR1 Granted Patent for Pharmaceutical Composition &... Feb 10 2016
XTL Biopharmaceuticals Joins Corporate Advisory Council of the Lupus Foundation of America Jan 27 2016
XTL Biopharmaceuticals Announces Encouraging Feedback from U.S. FDA on its Upcoming IND Filing for... Jan 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK